Product Pipeline
Our pipeline strategy is to build a risk-controlled clinical-stage pipeline with an exclusive focus on novel or highly differentiated biologics.
-
On-going
-
Planned
Uliledlimab (CD73 antibody)
More info- Indication
- Phase 1
- Phase 2
- Phase 3
- BLA
NSCLC
1L combo with toripalimab
Ovarian Cancer
2L combo with toripalimab
Solid Tumors
2L combo with atezolizumab
NSCLC
1L combo with chemo and CPI
Givastomig (Claudin 18.2 x 4-1BB bispecific antibody)
More info- Indication
- Phase 1
- Phase 2
- Phase 3
- BLA
GC/GEJ/EAC, PDAC
2L monotherapy
GC/GEJ/EAC
1L combo with chemo and CPI
TJ-L14B (PD-L1 x 4-1BB bispecific antibody)
More info- Indication
- Phase 1
- Phase 2
- Phase 3
- BLA
Solid Tumors
Monotherapy
Eftansomatropin Alfa (long-acting recombinant human growth hormone)
More info- Indication
- Phase 1
- Phase 2
- Phase 3
- BLA
PGHD
Monotherapy
Felzartamab (CD38 antibody)
More info- Indication
- Phase 1
- Phase 2
- Phase 3
- BLA
MM 3L monotherapy
(Registrational trial)
MM
2L TJ202 + Lenalidomide
Lemzoparlimab (CD47 antibody)
More info- Indication
- Phase 1
- Phase 2
- Phase 3
- BLA
MDS
1L combo with azacitidine
Abbreviations
- 1L = First line
- 2L = Second line
- 3L = Third line
- CPI = Checkpoint inhibitor
- EAC = Esophageal adenocarcinoma
- GC = Gastric cancer
- GEJ =Gastro-esophageal junction adenocarcinoma
- MDS = Myelodysplastic syndromes
- MM = Multiple myeloma
- NSCLC = Non-small cell lung cancer
- OC = Ovarian cancer
- PDAC = Pancreatic ductal adenocarcinoma
- PGHD = Pediatric growth hormone deficiency
Pipeline as of November 2023